Cadrenal Therapeutics, Inc.
CVKD
$5.47
$0.285.40%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -24.28% | -89.08% | -126.20% | -164.78% | -27.45% |
| Total Depreciation and Amortization | 263.16% | 219.05% | 191.30% | 183.33% | -5.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.74% | 213.47% | 260.27% | 207.58% | -69.60% |
| Change in Net Operating Assets | -169.99% | -69.55% | -75.40% | 180.51% | 1,198.20% |
| Cash from Operations | -71.28% | -88.82% | -148.87% | -157.21% | -108.41% |
| Capital Expenditure | 20.00% | -- | -- | -196.97% | -96.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 20.00% | -- | -- | -196.97% | -96.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 39.19% | 362.77% | 30.97% | 10.62% | -57.72% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -114.68% | 3,586.92% | -- | -- | -- |
| Cash from Financing | -26.54% | 647.53% | 87.98% | 68.58% | -24.56% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -472.05% | 89.38% | -70.48% | -69.68% | -80.70% |